CMPS will outperform MMED by at least 15% on a 6-month basis as psilocybin depression RCT data is absorbed by institutional allocators.

Compass Pathways' stock will perform better than MindMed's stock (by at least 15% over 6 months) because Compass just published strong depression trial results, while MindMed has weaker clinical data. Institutional money managers follow randomized controlled trial results, not hype—and Compass has cleaner evidence in a validated indication (depression).

Today's depression RCT directly validates Compass lead indication. MMED's 3.7% gain today is retail momentum — institutional money follows randomized controlled trial data, not hype. CMPS has cleaner regulatory story.